Trial Profile
A Real-world, retrospective study on the safety and efficacy of apixaban, dabigatran and rivaroxaban compared to warfarin in patients with non-valvular atrial fibrillation (NVAF): the REVISIT-US study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 May 2017
Price :
$35
*
At a glance
- Drugs Apixaban (Primary) ; Dabigatran etexilate (Primary) ; Rivaroxaban (Primary) ; Warfarin
- Indications Stroke
- Focus Adverse reactions; Therapeutic Use
- Acronyms REVISIT-US
- 28 Apr 2017 Results related to secondary prevention of stroke or systemic embolism presented at the 69th Annual Meeting of the American Academy of Neurology
- 22 Nov 2016 New trial record